Cargando…

Current Landscape and the Potential Role of Hypoxia-Inducible Factors and Selenium in Clear Cell Renal Cell Carcinoma Treatment

In the last two decades, the discovery of various pathways involved in renal cell carcinoma (RCC) has led to the development of biologically-driven targeted therapies. Hypoxia-inducible factors (HIFs), angiogenic growth factors, von Hippel–Lindau (VHL) gene mutations, and oncogenic microRNAs (miRNAs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garje, Rohan, An, Josiah J., Sanchez, Kevin, Greco, Austin, Stolwijk, Jeffrey, Devor, Eric, Rustum, Youcef, Zakharia, Yousef
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321165/ https://www.ncbi.nlm.nih.gov/pubmed/30513765 http://dx.doi.org/10.3390/ijms19123834

Ejemplares similares

The Future of Immunotherapy-Based Combination Therapy in Metastatic Renal Cell Carcinoma
por: Garje, Rohan, et al.
Publicado: (2020)

Understanding the Redox Biology of Selenium in the Search of Targeted Cancer Therapies
por: Stolwijk, Jeffrey M., et al.
Publicado: (2020)

Selenium targets resistance biomarkers enhancing efficacy while reducing toxicity of anti-cancer drugs: preclinical and clinical development
por: Zakharia, Yousef, et al.
Publicado: (2018)

Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma—Bench-to-Bedside Therapy
por: Rustum, Youcef M., et al.
Publicado: (2018)

MicroRNA Expression in Clear Cell Renal Cell Carcinoma Cell Lines and Tumor Biopsies: Potential Therapeutic Targets
por: Swearson, Samuel, et al.
Publicado: (2022)

Potential Role of Selenium in the Treatment of Cancer and Viral Infections
por: Rataan, Aseel O., et al.
Publicado: (2022)

Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition
por: Chintala, Sreenivasulu, et al.
Publicado: (2012)

Druggable Biomarkers Altered in Clear Cell Renal Cell Carcinoma: Strategy for the Development of Mechanism-Based Combination Therapy
por: Rustum, Youcef M., et al.
Publicado: (2023)

Patient Characteristics and Survival Outcomes of Non-Metastatic, Non-Clear Cell Renal Cell Carcinoma
por: An, Josiah, et al.
Publicado: (2022)

Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer
por: Garje, Rohan, et al.
Publicado: (2020)

PARP Inhibitors in Prostate and Urothelial Cancers
por: Garje, Rohan, et al.
Publicado: (2020)

Non–Muscle Invasive Papillary Urothelial Carcinoma Metastatic to the Mandible
por: Frydenlund, Noah, et al.
Publicado: (2018)

Mapping the immune environment in clear cell renal carcinoma by single-cell genomics
por: Borcherding, Nicholas, et al.
Publicado: (2021)

The renal clear cell carcinoma immune landscape
por: Saad, Omar A., et al.
Publicado: (2022)

The epigenetic landscape of clear-cell renal cell carcinoma
por: Kluzek, Katarzyna, et al.
Publicado: (2015)

Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature
por: John, Alexius, et al.
Publicado: (2023)

Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer
por: Garje, Rohan, et al.
Publicado: (2019)

Multivariable Analysis of 169 Cases of Advanced Cutaneous Melanoma to Evaluate Antibiotic Exposure as Predictor of Survival to Anti-PD-1 Based Immunotherapies
por: Swami, Umang, et al.
Publicado: (2020)

Immune Infiltration Landscape in Clear Cell Renal Cell Carcinoma Implications
por: Wang, Yongfeng, et al.
Publicado: (2021)

Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma
por: Kim, Myung-Chul, et al.
Publicado: (2021)

The intrarenal landscape of T cell receptor repertoire in clear cell renal cell cancer
por: Zhang, Wei, et al.
Publicado: (2022)

Comprehensive Genomic Landscape in Chinese Clear Cell Renal Cell Carcinoma Patients
por: Huang, Jiwei, et al.
Publicado: (2021)

Landscape of immune cell infiltration in clear cell renal cell carcinoma to aid immunotherapy
por: Bai, Dan, et al.
Publicado: (2021)

The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy
por: van der Mijn, Johannes C., et al.
Publicado: (2022)

The stratification and prognostic importance of molecular and immune landscapes in clear cell renal cell carcinoma
por: Zhai, Xinyu, et al.
Publicado: (2023)

Selenium in Cattle: A Review
por: Mehdi, Youcef, et al.
Publicado: (2016)

Link between dysregulated hypoxia signaling and aberrant methylation in clear cell renal cell carcinoma?
por: Shenoy, Niraj
Publicado: (2017)

Construction and Verification of a Combined Hypoxia and Immune Index for Clear Cell Renal Cell Carcinoma
por: Wang, Bin, et al.
Publicado: (2022)

Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy
por: Venur, Vyshak Alva, et al.
Publicado: (2017)

Novel landscape of HLA‐G isoforms expressed in clear cell renal cell carcinoma patients
por: Tronik‐Le Roux, Diana, et al.
Publicado: (2017)

First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape
por: Gulati, Shuchi, et al.
Publicado: (2022)

Identification and Quantification of Necroptosis Landscape on Therapy and Prognosis in Kidney Renal Clear Cell Carcinoma
por: Xin, Sheng, et al.
Publicado: (2022)

Identification of anoikis-related subtypes and immune landscape in kidney renal clear cell carcinoma
por: Ding, Wencong, et al.
Publicado: (2023)

Clearing up Clear Cell: Clarifying the Immuno-Oncology Treatment Landscape for Metastatic Clear Cell RCC
por: Doppalapudi, Sai Krishnaraya, et al.
Publicado: (2021)

Identification and validation of a hypoxia-related prognostic signature in clear cell renal cell carcinoma patients
por: Li, Zhengtian, et al.
Publicado: (2021)

Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review
por: Greco, Austin, et al.
Publicado: (2019)

Non-Clear Cell Renal Cell Carcinoma: Current Management and Best Practice
por: Salgia, Meghan, et al.
Publicado: (2017)

Proteotranscriptomic Analysis Reveals Stage Specific Changes in the Molecular Landscape of Clear-Cell Renal Cell Carcinoma
por: Neely, Benjamin A., et al.
Publicado: (2016)

Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma
por: de Velasco, Guillermo, et al.
Publicado: (2018)

The Landscape of Iron Metabolism-Related and Methylated Genes in the Prognosis Prediction of Clear Cell Renal Cell Carcinoma
por: Mou, Yanhua, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7kvkcm8fh2hdlcrk8vhd5dg0pu